Development of vaccines against Helicobacter pylori

Expert Review of Vaccines

Volumn 8, Issue 8, 2009, Pages 1037-1049

  Del Giudice, Giuseppe ^a   Malfertheiner, Peter ^b   Rappuoli, Rino ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Adjuvant; Antibody response; Cellular response; Helicobacter pylori; Pathogenesis; Recombinant protein; Vaccine; Vaccine delivery

Indexed keywords

ALPA PROTEIN; ALUMINUM HYDROXIDE; BABA PROTEIN; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIAL TOXIN; BACTERIAL VACCINE; BACTERIAL VECTOR; BACTERIUM LYSATE; CAGA PROTEIN; CD45RO ANTIGEN; CD69 ANTIGEN; CHOLERA TOXIN; CXCL1 CHEMOKINE; CYTOTOXIN; HELICOBACTER PYLORI VACCINE; HPAA PROTEIN; IMMUNOGLOBULIN A; INACTIVATED VACCINE; LT TOXIN; LTR 192 G; NUCLEOSOME ASSEMBLY PROTEIN; RECOMBINANT ENZYME; RECOMBINANT PROTEIN; SABA PROTEIN; UNCLASSIFIED DRUG; UREASE; VACUOLATING TOXIN; VIRULENCE FACTOR;

ADJUVANT THERAPY; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; ANTIBODY TITER; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CD4+ T LYMPHOCYTE; DIARRHEA; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG MEGADOSE; DRUG WITHDRAWAL; EFFECTOR CELL; ENCAPSULATION; EXPERIMENTAL MODEL; HELICOBACTER FELIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE REACTION; INNATE IMMUNITY; LOW DRUG DOSE; MOLECULAR MECHANICS; NAUSEA; NONHUMAN; PATHOGENESIS; PATHOGENICITY ISLAND; PEPTIC ULCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REPEATED DRUG DOSE; REVIEW; SALMONELLA TYPHI; STOMACH; STOMACH CANCER; TH1 CELL; TH2 CELL;

BACTERIAL VACCINES; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; VACCINES, SUBUNIT;

EID: 68049121803     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.62     Document Type: Review

References (124)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulcer. Lancet I, 1311-1315 (1984).
2. Bruce MG, Maaroos HI. Epidemiology of Helicobacter pylori infection. Helicobacter 13(Suppl. 1), 1-6 (2008).
3. Graham DY, Malaty HM, Evans DG et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 100, 1595-1601 (1991).
4. Frenck RW Jr, Clemens J. Helicobacter pylori in the developing world. Microbes Infect. 5, 705-713 (2003).
5. Rothenbacher D, Bode G, Berg G, Knwyer U, Gonser T. Helicobacter pylori among preschool children and their parents: evidence of parent-child transmission. J. Infect. Dis. 179, 398-402 (1999).
6. Rothenbacher D, Inceoglu J, Bode G, Brenner H. Acquisition of Helicobacter pylori infection in a high-risk population occurs within the first 2 years of life. J. Pediatr. 136, 744-748 (2000).
7. Malaty HM, Kumagai T, Tanaka E, Ota H, Kiyosawa K. Evidence form a nine-year birth cohort study in Japan of transmission pathways of Helicobacter pylori infection. J. Clin. Microbiol. 38, 1971-1973 (2000).
8. Schwarz S, Morelli G, Kusecek B et al. Horizontal versus familial transmission of Helicobacter pylori. PLoS Pathog. 4, e1000180 (2008). • Genetic analysis of Heliobacter pylori showing the possibility of horizontal transmission in areas of high prevalence of infection in developing countries.
9. Parsonnet J, Shmuely H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA 282, 2240-2245 (1999).
10. Leung WK, Siu KLK, Kwok CKL, Chan SY, Sung, R, Sung JJY. Isolation of Helicobacter pylori from vomitus in children and its implication in gastro-oral transmission. Am. J. Gastroenterol. 94, 2881-2884 (1999).
11. Miehlke S, Thomas R, Gutierrez O, Graham DY, Go MF. DNA fingerprinting of single colonies of Helicobacter pylori from gastric cancer patients suggests infection with a single predominant strain. J. Clin. Microbiol. 37, 245-247 (1999).
12. Parsonnet J, Friedman G, Vandersteen D et al. Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 325, 1127-1131 (1991).
13. Kuipers EJ, Uyterlinde AM, Pena AS et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 345, 1525-1528 (1995).
14. Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 133, 659-672 (2007).
15. Kandulski A, Selgrad M, Malfertheiner P. Helicobacter pylori infection: a clinical overview. Dig. Liver Dis. 40, 619-626 (2008).
16. Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology 128, 1579-1605 (2005).
17. Sagaert X, De Wolf-Peeters C, Noels H, Baens M. The pathogenesis of MALT lymphomas: where do we stand? Leukemia 21, 389-396 (2007).
18. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht III Consensus Report. Gut 56, 772-781 (2007).
19. Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomized controlled trial. Lancet 372, 392-397 (2008). • Positive effect of H. pylori eradication on resection of early gastric cancer.
20. Vakil N, Mégraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 133, 985-1001 (2007).
21. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology 118, S2-S8 (2000).
22. Collins J, Ali-Ibrahim A, Smoot DT. Antibiotic therapy for Helicobacter pylori. Med. Clin. North Am. 90, 1125-1140 (2006).
23. Gerrits MM, van Vliet AH, Kuipers EJ et al. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect. Dis. 11, 699-709 (2007).
24. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat. Clin. Pract. Gastroenterol. Hepatol. 5, 321-331 (2008).
25. Parsonnet J. What is the Helicobacter pylori global re-infection rate? Can. J. Gastroenterol. 17(Suppl. B), 46B-48B (2003).
26. Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am. J. Gastroenterol. 100, 2083-2099 (2005).
27. Rupnow MF, Owens DK, Shachter R, Parsonnet J. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine methodology. Helicobacter 4, 272-280 (1999).
28. Rupnow MF, Shachter R, Owens DK, Parsonnet J. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine 20, 879-885 (2002).
29. Vaccines for the 21th Century: a Tool for Decision Making. Stratton KR, Durch JS, Lawrence RS (Eds). Institute of Medicine. National Academy Press, Washington, DC, USA, 181-188 (2001).
30. Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaptation of the species. Int. J. Antimicrob. Agents 32, 199-206 (2008).
31. Sullivan PB, Thomas JE, Wight DG et al. Helicobacter pylori in Gambian children with chronic diarrhoea and malnutrition. Arch. Dis. Child 65, 189-191 (1990).
32. Dale A, Thomas JE, Darboe MK, Coward WA, Harding M, Weaver LT. Helicobacter pylori infection, gastric acid secretion, and infant growth. J. Pediatr. Gastroenterol. Nutr. 26, 393-397 (1998).
33. Windle HJ, Kelleher D, Crabtree JE. Childhood Helicobacter pylori infection and growth impairement in developing countries: a vicious cycle? Pediatrics 119, e754-e759 (2008).
34. Passaro DJ, Taylor DN, Meza R, Cabrera L, Gilman RH, Parsonnet J. Acute Helicobacter pylori infection is followed by an increase in diarrheal disease among Peruvian children. Pediatrics 108, E87 (2001).
35. Shahinian ML, Passaro DJ, Swerdlow DL, Mintz ED, Rodriguez M, Parsonnet J. Helicobacter pylori and epidemic Vibrio cholerae 01 infection in Peru. Lancet 355, 377-378 (2000).
36. Bhan MK, Bahl R, Sazawal S et al. Association between Helicobacter pylori infection and increased risk of typhoid fever. J. Infect. Dis. 186, 1857-1860 (2002).
37. Del Giudice G, Covacci A, Telford JL, Montecucco C, Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Annu. Rev. Immunol. 19, 523-563 (2001).
38. O'Rourke JL, Lee A. Animal models of Helicobacter pylori infection and disease. Microbes Infect. 5, 741-748 (2003).
39. Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA 103, 10834-10839 (2006).
40. Sabarth N, Hurwitz R, Meyer TF, Bumann D. Multiparameter selection of Helicobacter pylori antigens identifies two novel antigens with high protective efficacy. Infect. Immun. 70, 6499-6503 (2002).
41. Moise L, McCurrey JA, Pappo J et al. Identification of genome-derived vaccine candidates conserved between human and mouse-adapted strains of H. pylori. Hum. Vaccines 4, 219-223 (2008).
42. Mobley HLT. Urease. In: Helicobacter pylori. Physiology and genetics. Mobley HLT, Mendz GL, Hazell SL (Eds). ASM Press, Washington DC, USA 179-191 (2001).
43. Leal-Herrera Y, Torres, J, Perez-Perez G et al. Serologic IgG response to urease in Helicobacter pylori-infected persons from Mexico. Am. J. Trop. Med. Hyg. 60, 587-592 (1999).
44. D'Elios MM, Manghetti M, Almerigogna F et al. Different cytokine profile and antigenspecificity repertoire in Helicobacter pylorispecific T cell clones from the antrum of chronic gastritis patients with or without peptic ulcer. Eur. J. Immunol. 27, 1751-1755 (1997).
45. Lucas B, Bumann D, Walduck A et al. Adoptive transfer of CD4+ T cells specific for subunit A of Helicobacter pylori urease reduces H. pylori stomach colonization in mice in the absence of interlekin-4 (IL-4)/ IL-13 receptor signaling. Infect. Immun. 69, 1714-1721 (2001).
46. Bagnoli F, Buti L, Tompkins L, Covacci A, Amieva MR. Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes in MDCK cells. Proc. Natl Acad. Sci. USA 102, 16339-16344 (2005).
47. Backert S, Selbach M. Role of type IV secretion in Helicobacter pylori pathogenesis. Cell Microbiol. 10, 1573-1581 (2008).
48. Hatakeyama M. Saga of CagA in Helicobacter pylori pathogenesis. Curr. Opin. Microbiol. 11, 30-37 (2008).
49. Ogura K, Maeda S, Nakao M et al. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbils. J. Exp. Med. 192, 1601-1610 (2000).
50. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between CagA seropositivity and gastric cancer. Gastroenterology 125, 1636-1644 (2003).
51. Palli D, Masala G, Del Giudice G et al. CagA+ Helicobacter pylori infection and gastric cancer risk in the EPICEURGAST study. Int. J. Cancer 120, 85-867 (2006).
52. Montecucco C, Rappuoli R. Living dangerously: how Helicobacter pylori survives in the human stomach. Nat. Rev. Mol. Cell Biol. 2, 457-466 (2001).
53. De Bernard M, Cappon A, Del Giudice G, Rappuoli R, Montecucco C. The multiple cellular activities of the VacA cytotoxin of Helicobacter pylori. Int. J. Med. Microbiol. 293, 589-597 (2004).
54. Cover TL, Blanke SR. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat. Rev. Microbiol. 3, 320-332 (2005).
55. Gangwer KA, Mushrush DJ, Stauff DL et al. Crystal structure of the Helicobacter pylori vacuolating toxin p55 domain. Proc. Natl Acad. Sci. USA 104, 16293-16298 (2007). • Definition of the structure of the p55 moiety of the H. pylori cytotoxin.
56. Salama N, Otto G, Tompkins L, Falkow S. Vacuolating cytotoxin of Helicobacter pylori plays a role during colonization in a mouse model of infection. Infect. Immun. 69, 730-736 (2001).
57. Papini E, Satin B, Norais N et al. Selective increase of the permeability of polarized epithelial cell monolayers by Helicobacter pylori vacuolating toxin. J. Clin. Invest. 102, 813-820 (1998).
58. Molinari M, Sallio M, Galli C et al. Selective inhibition of Ii-dependent antigen presentation ny Helicobacter pylori toxin Vac A. J. Exp. Med. 187, 135-140 (1998).
59. Shirai M, Arichi T, Nakazawa T, Berzofsky JA. Persistent infection by Helicobacter pylori down-modulates virus-specific CD8+ cytotoxic T cell response and prolongs viral infection. J. Infect. Dis. 177, 72-80 (1998).
60. Gebert B, Fischer W, Weiss E, Hoffman R, Haas R. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science 301, 1099-1102 (2003).
61. Boncristiano M, Paccani SR, Barone S et al. The Helicobacter pylori cytotoxin inhibits T cell activation by two independent mechanisms. J. Exp. Med. 198, 1887-1897 (2003).
62. Zanotti G, Papinutto E, Dundon W et al. Structure of the neutrophil-activating protein of Helicobacter pylori. J. Mol. Biol. 323, 125-130 (2002).
63. D'Elios MM, Amedei A, Cappon A, Del Prete G, de Bernard M. The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent. FEMS Immunol. Med. Microbiol. 50, 157-164 (2007).
64. Amedei A, Cappon A, Codolo G et al. The neutrophil activating protein of Helicobacter pylori promotes Th1 immune responses. J. Clin. Invest. 116, 1092-1101 (2006). • The H. pylori neutrophil-activating protein (NAP) shown to act as a Toll-like receptor-2 agonist and to promote differentiation of Th1-type cells.
65. Del Prete G, Chiumiento L, Amedei A et al. Immunouppression of Th2 responses in Trichinella spiralis infection by Helicobacter pylori neutrophil-activating protein. J. Allergy Clin. Immunol. 122, 908-913 (2008). • H. pylori NAP shown to divert the Th2-type response to a parasite towards a Th1 response.
66. Codolo G, Mazzi P, Amedei A et al. The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma. Cell Microbiol. 10, 2355-2363 (2008).
67. Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 134, 306-323 (2008).
68. Solnick JV, Schauer DB. Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol. Rev. 14, 59-97 (2001).
69. Graham DY, Opekun AR, Osato MS et al. Challenge model for Helicobacter pylori infection in human volunteers. Gut 53, 1235-1243 (2004). • After the pioneer work of self-infection by Marshall and by Morris [99,100], this was the the first report of an experimental infection of healthy H. pylori-negative subjects, with the purpose of using this model in vaccination studies.
70. Nurgalieva ZZ, Conner ME, Opekun AR et al. B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans. Infect. Immun. 73, 2999-3006 (2005). • Analysis of antibody and T-cell responses in the individuals experimentally infected with H. pylori in [69].
71. Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. Gastroenterology 130, 188-206 (2006).
72. Smythies LE, Waites KB, Lindsey JR, Harris PR, Ghiara P, Smith PD. Helicobacter pylori-induced mucosal inflammation is Th1-mediated and exacerbated in IL-4, but not in IFN-g gene-deficient mice. J. Immunol. 165, 1022-1029 (2000).
73. Eisenberg JC, Czinn SJ, Garhart CA et al. Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal mice. Infect. Immun. 71, 1820-1827 (2003).
74. Akhiani AA, Schoen K, Lycke N. Vaccine-induced immunity against Helicobacter pylori infection is impaired in IL-18-deficient mice. J. Immunol. 173, 3348-3356 (2004).
75. Akhiani AA, Stensson A, Schoen K, Lycke N. IgA antibodies impair resistance against Helicobacter pylori infection: studies on immune evasion in IL-10-deficient mice. J. Immunol. 174, 8144-8153 (2005).
76. Lundin BS, Enarsson K, Kindlund B et al. The local and systemic T-cell response to Helicobacter pylori in gastric patients is characterized by production of intelreukin-10. Clin. Immunol. 125, 205-213 (2007).
77. Akhiani AA, Pappo J, Kabok Z et al. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J. Immunol. 169, 6977-6984 (2002).
78. Taylor JM, Ziman ME, Fong J, Solnick JV, Vajdy M. Possible correlates of long-term protection against Helicobacter pylori following systemic or combinations of mucosal and systemic immunizations. Infect. Immun. 75, 3462-3469 (2007).
79. Raghavan S, Fredriksson M, Svennerholm AM, Holmgren J, Suri-Payer E. Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clin. Exp. Immunol. 132, 393-400 (2003).
80. Rad R, Brenner L, Bauer S et al. CD25+/FoxP3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology 131, 525-537 (2006).
81. Enarsson K, Lundgren A, Kindlund B et al. Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clin. Immunol. 121, 358-368 (2006).
82. Enarsson K, Lundin BS, Johnsson, E, Brezicka T, Quiding-Jaerbrink M. CD4+CD25high regulatory T cells reduce T cell transendothelial migration in cancer patients. Eur. J. Immunol. 37, 282-291 (2007).
83. Robinson K, Kenefeck R, Pidgeon EL et al. Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut 57, 1375-1385 (2008). • Regulatory T cells and their potential association with peptic ulcer disease.
84. Harris PR, Wright SW, Serrano C et al. Helicobacter pylori gastritis in children is associated with a regulatory T-cell response. Gastroenterology 134, 491-499 (2008). • Regulatory T cells potentially associated with differential pathology by H. pylori observed in children as compared with adults.
85. Chak E, Rutherford GW, Steinmaus C. The role of breast-feeding in the prevention of Helicobacter pylori infection: a systematic review. Clin. Infect. Dis. (2009) (Epub ahead of print).
86. Ermak TH, Giannasca PJ, Nichols R et al. Immunization of mice with ureas vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J. Exp. Med. 188, 2277-2288 (1998).
87. Senn BM, Lopez-Macias C, Kalinke U et al. Combinatorial immunoglobulin light chain variability creates sufficient B cell diversity to mount protective antibody responses against pathogen infections. Eur. J. Immunol. 33, 950-961 (2003).
88. Gottwein JM, Blanchard TG, Targoni OS et al. Protective anti-Helicobacter pylori immunity is induced by aluminium hydroxide or complete Freund's adjuvant by systemic immunization. J. Infect. Dis. 184, 308-314 (2001).
89. Eaton KA, Mefford ME. Cure of Helicobacter pylori infection and resolution of gastritis by adoptive transfer of splenocytes in mice. Infect. Immun. 69, 1025-1031 (2001).
90. Garhart CA, Nedrud JG, Heinzel FP, Sigmund NE, Czinn SJ. Vaccine-induced protection against Helicobacter pylori in mice lacking both antibodies and interleukin-4. Infect. Immun. 71, 3628-3633 (2003).
91. Hoffman PS, Vats N, Hutchison D et al. Development of aninterleukin-12-deficinet mouse model that is permissive for colonizationby a motile KE26695 strain of Helicobacter pylori. Infect. Immun. 71, 2534-2541 (2003).
92. Garhart CA, Heinzel FP, Czinn SJ, Nedrud JG. Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin-12-dependent but g interferon and inducible nitric oxide synthase independent. Infect. Immun. 71, 910-921 (2003).
93. Panthel K, Faller G, Haas R. Colonization of C57BL/6J and BALB/c wild type and knockout mice with Helicobacter pylori: effect of vaccination and implications for innate and acquired immunity. Infect. Immun. 71, 794-800 (2003).
94. Raghavan S, Svennerhom AM, Holmgren J. Effects of oral vaccination and immunomodulation by cholera toxin on experimental H. pylori infection, reinfection, and gastritis. Infect. Immun. 70, 4621-4627 (2002).
95. Delyria ES, Redline RW, Blanchard TG. Vaccination of mice against H. pylori induces a strong Th-17 response and immunity that is neutrophil- dependent. Gastroenterology 136, 247-256 (2009). • Demonstration in mice that Th17 responses intervene in the effector mechanisms leading to immunity against H. pylori.
96. Velin D, Favre L, Bernasconi E et al. Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology 136(7), 2237-2246 (2009). • IL-17 as a key mediator of vaccine-induced immunity against Helicobacter infection.
97. Mueller A, O'Rourke J, Chu P et al. Protective immunity against Helicobacter is characterized by a unique transcriptional signature. Proc. Natl Acad. Sci. USA 100, 12289-12294 (2003). • First demonstration by gene profiling that adipocyte-associated genes may be involved in the state of immunity (in mice) to H. pylori.
98. Walduck A, Schmitt A, Lucas B et al. Transciption profiling analysis of the mechanisms of vaccine-induced protection against H. pylori. FASEB J. 18, 1955-1957 (2004).
99. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulate for pylori Campylobacter. Med. J. Aust. 142, 436-439 (1985).
100. Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am. J. Gastroenterol. 82, 192-199 (1987).
101. Aebischer T, Dumann D, Epple HJ et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut 57, 1065-1072 (2008). • First study reporting results of an experimental challenge with H. pylori [69,70] in healthy volunteers previously immunized with a Salmonella strain bearing urease.
102. Moran AP, Prendergast MM. Molecular mimicry in Campylobacter jejuni and Helicobacter pylori lipopolysaccharides: contribution of gastrointestinal infections to autoimmunity. J. Autoimmun. 16, 241-256 (2001).
103. D'Elios MM, Appelmelk BJ, Amedei A, Bergman MP, Del Prete G. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol. Med. 10, 316-323 (2004).
104. Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, Di Lorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69, 3581-3590 (2001).
105. Losonsky G, Kotloff KL, Walker RI. B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LTR192G in H. pylori seronegative individuals. Vaccine 21, 562-565 (2003).
106. Pizza M, Giuliani MM, Fontana MR et al. Mucosal vaccines: non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccines 19, 2534-2541 (2001).
107. Tribble DR, Baqar S, Trespalacios F et al. Safety and immunogenicity of a 4-dose short interval oral, inactivated whole-cell Campylobacter vaccine co-administered with modified Escherichia coli heat-labile (LTR192G) adjuvant in volunteers. Presented at: Fourth Annual Conference on Vaccine Research. Arlington, VA, USA, 23-25 April 2001 (Abstract S39).
108. Michetti P, Kreiss C, Kotloff KL et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116, 804-812 (1999).
109. Banerjee S, Medina-Fatimi A, Nichols R et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease-based oral immunization against Helicobacter pylori in healthy volunteers. Gut 51, 634-640 (2002).
110. Kleanthous H, Myers GA, Georgakopoulos KM et al. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect. Immun. 66, 2879-2886 (1998).
111. Sougioultzis S, Lee CK, Alsahli M et al. Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 21, 194-201 (2002).
112. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 18, 449-459 (2002).
113. Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. 68, 2135-2141 (2000).
114. Bumann D, Metzger WG, Mansouri E et al. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 20, 845-852 (2002).
115. Metzger WG, Mansouri E, Kronawitter M et al. Impact of vector priming on the immunogenicity of a live recombinant Salmonella enterica serovar Typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in humans volunteers. Vaccine 22, 2273-2277 (2004).
116. Sanchez V, Gimenez S, Haensler J et al. Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones. FEMS Immunol. Med. Microbiol. 30, 157-165 (2001).
117. Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet 367, 1926-1936 (2006).
118. Maione D, Margarit I, Rinaudo CD et al. Identification of a universal group B streptococcus vaccine by multiple menome screen. Science 309, 148-150 (2005).
119. Rossi G, Ruggiero P, Peppoloni S et al. Therapeutic vaccination against Helicobacter pylori in the Beagle dog experimental model: safety, immunogenicity, and efficacy. Infect. Immun. 72, 3252-3259 (2004).
120. Ferrero RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc. Natl Acad. Sci. USA 92, 6499-6503 (1995).
121. Malfertheiner P, Schultze V, Rosenkranz B et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a Phase I study. Gastroenterology 135, 787-895 (2008). • Report of a Phase I study in H. pylorinegative subjects immunized intramuscularly with an alumadjuvanted vaccine consisting of the association of three antigens, VacA, CagA and NAP.
122. Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. Helicobacter pylori virulence and genetic geography. Science 284, 1328-1333 (1999). • First demonstration of the association of the genetic of H. pylori and the migration of human populations.
123. Linz B, Balloux F, Moodley Y et al. An African origin for the intimate association between humans and Helicobacter pylori. Nature 445, 915-918 (2007). • Further demonstration of the genetic geography of H. pylori.
124. Moodley Y, Linz, B, Yamaoka Y et al. The peopling of the Pacific from a bacterial perspective. Science 323, 527-530 (2009). • Extension of this association to the migration of humans in the Pacific area.